Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Valuing and Structuring Pharmaceutical Licensing Agreements
This publication provides an essential grounding in how to use accepted and reliable methods for valuing pharmaceutical and biotech projects. Whether you are about to negotiate a licensing deal or need to perform a rigorous portfolio review, it is vital that you understand both the value of a project today and how that value can be built over time.
The methods presented here provide answers to both questions through the combination of historical analysis of what the market has been willing to pay for similar products and technologies, and forward looking projections that explicitly handle the issues of risk, time, cost and reward.
Potential elements of deals are also discussed, as are the appropriate levels of risk and reward sharing, and the significance of individual company needs and preferences. When incorporated into the valuation models that have been built, these elements will permit the development of deal structures that are attractive to both sides.
This publication is designed for:
> Business development and licensing executives in pharmaceutical, biotech and drug delivery companies.
> Technology transfer managers at universities and not-for-profit institutions.
> R&D managers who wish to perform more rigorous economic portfolio analysis.
> Anyone negotiating or about to negotiate a product or technology deal.
> Anyone needing a robust and transparent method for portfolio analysis.
Hard Copy
Table of Contents
Price: $1,795.00 / GBP897.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.